Healthcare Services

Global Neuroendocrine Carcinoma Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Neuroendocrine Carcinoma Market At The End Of The 2026–2030 Forecast Period?

The neuroendocrine carcinoma market has experienced significant expansion in recent years. Its valuation is set to increase from $1.75 billion in 2025 to $1.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to the rising incidence of neuroendocrine carcinoma, greater application of imaging for prompt detection, the early implementation of surgical tumor removal, the formulation of initial chemotherapy approaches, and an expanding clinical understanding of nec subtypes.

The neuroendocrine carcinoma market is anticipated to demonstrate robust growth in the upcoming years, with projections indicating it will reach $2.47 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is fueled by several factors, including the expanding use of targeted biologic therapies, increasing investment in immunotherapy research, the growing availability of precision diagnostic tools, the development of advanced radiotherapy systems, and the rising adoption of multidisciplinary oncology centers. Significant trends expected during this period encompass the rising adoption of chemotherapy for aggressive tumor management, increasing use of targeted therapies in advanced nec cases, growing utilization of radiotherapy for localized tumor control, the expansion of biopsy and serology-based diagnostic approaches, and an increasing demand for multidisciplinary treatment planning.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp

Which Market Drivers Are Supporting The Expansion Of The Neuroendocrine Carcinoma Market?

The neuroendocrine carcinoma market is anticipated to expand as targeted therapies gain traction. These therapies are specific treatments engineered to precisely identify and disrupt the molecular processes or genetic alterations that contribute to a disease, particularly cancer. The increasing demand for targeted therapies stems from their ability to accurately treat specific genetic mutations, advancements in personalized medicine, and their capacity to deliver improved patient outcomes with fewer adverse effects. For neuroendocrine carcinoma, these therapies facilitate the development of treatments that specifically target the tumor’s genetic and biochemical profiles, thereby enhancing both precision and effectiveness. For instance, in July 2023, data published by the American Society of Gene & Cell Therapy (ASGCT) and Citeline showed that the number of gene therapies in Phase II rose by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2. This growth in targeted therapies is thus a key driver for the neuroendocrine carcinoma market.

What Segment Types Make Up The Neuroendocrine Carcinoma Market?

The neuroendocrine carcinoma market covered in this report is segmented –

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma

2) By Diagnostic Tools: Imaging, Biopsy, Serology

3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers

Subsegments:

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors

3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

What Trends Are Projected To Affect The Neuroendocrine Carcinoma Market?

Leading firms within the neuroendocrine carcinoma sector are concentrating on creating innovative treatments, like targeted radiopharmaceutical therapy, aiming to enhance the accuracy of treatment and results for patients. This specific therapy utilizes radioactive molecules designed to precisely target and deliver radiation to cancer cells, thereby reducing damage to healthy tissues. An example of this is Abdera Therapeutics Inc., a Canadian biotechnology firm, which in September 2024, obtained orphan drug designation from the Food and Drug Administration (FDA) for its product ABD-147, intended for treating neuroendocrine carcinoma. ABD-147 is engineered to selectively home in on tumors that express the DLL3 protein, which is frequently elevated in aggressive forms of neuroendocrine cancers, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Such a designation provides substantial benefits for development, such as tax credits for conducting clinical trials and the possibility of market exclusivity, thus establishing ABD-147 as a hopeful therapeutic option within this particular oncology field.

Who Are The Key Players Driving Competition In The Neuroendocrine Carcinoma Market?

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

Read the full neuroendocrine carcinoma market report here:

https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report

How Is The Neuroendocrine Carcinoma Market Distributed Across Key Geographic Regions?

North America was the largest region in the neuroendocrine carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuroendocrine Carcinoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp

Browse Through More Reports Similar to the Global Neuroendocrine Carcinoma Market 2026, By The Business Research Company

Nephrologists Market Global Report 2020 2030 Covid 19 Implications And Growth

https://www.thebusinessresearchcompany.com/report/nephrologists-market-global-report-2020-2030-covid-19-implications-and-growth

Nephrologists Market Global Report 2020 2030 Covid 19 Implications And Growth

https://www.thebusinessresearchcompany.com/report/nephrologists-market-global-report-2020-2030-covid-19-implications-and-growth

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795